Lysosomal Acidification Failure: Convergent GBA1/LAMP2A–mediated Autophagy Dysfunction Links PD and AD Clinical Progression

Convergence hypothesis: Lysosomal acidification failure, driven by convergence of GBA1 (PD) and LAMP2A (AD) dysfunction, represents a convergent node in the autophagy-lysosomal pathway that unifies PD and AD progression.

PD-specific mechanism: GBA1 encodes glucocerebrosidase, which hydrolyzes glucosylceramide to ceramide and glucose. In PD, GBA1 mutations (N370S, L444P) reduce enzymatic activity, causing glucosylceramide accumulation that stabilizes α-synuclein oligomers at the lysosomal membrane, blocking autophagosome-lysosome fusion. This impairs clearance of damaged mitochondria (via PINK1/Parkin) and increases exosomal α-synuclein release. LIMP2 (SCARB2) trafficking of GBA1 to lysosomes is also disrupted.

AD-specific mechanism: LAMP2A (Lysosomal Associated Membrane Protein 2A) mediates chaperone-mediated autophagy (CMA), the only autophagy pathway that degrades individual cytosolic proteins without membrane wrapping. In AD, phosphorylated tau (pThr231, pSer396) binds to LAMP2A with high affinity, blocking its ability to import other substrates including Hsp90, GAPDH, and itself. This creates a feed-forward loop: tau blocks LAMP2A → tau accumulates → more tau blocks LAMP2A. Additionally, APP/Abeta impairs lysosomal acidification via the V-ATPase (ATP6AP1/ATP6V0A1), further suppressing all lysosomal degradation.

Shared molecular targets (2+ per disease): • GBA1 (PD: glucocerebrosidase, lysosomal enzyme) ↔ LAMP2A (AD: chaperone-mediated autophagy) — both converge on lysosomal degradation • Glucosylceramide (PD, elevated) ↔ Ceramide (AD, elevated via ASM/ASR) — shared lipid accumulation • LIMP2/SCARB2 (PD: GBA1 trafficking to lysosome) ↔ ATP6V0A1 (AD: V-ATPase subunit for lysosomal acidification) — shared lysosomal maturation • TFEB (PD: master transcriptional regulator of lysosomal biogenesis; AD: same inhibition) — shared transcription factor • CTSB/CTSD (PD: cathepsins B/D for autophagy; AD: same) — shared lysosomal proteases reduced in both diseases

Falsifiable predictions:

1. In GBA1 L444P iPSC-derived neurons, LAMP2A overexpression will rescue both α-synuclein (Ser129-P) clearance and mitochondrial complex I activity.
2. Post-mortem PD caudate and AD superior temporal gyrus both show reduced mature cathepsin D (active form) by >60% vs. age-matched controls, with accumulation of the pro-cathepsin D form.
3. A dual GBA1 agonist + LAMP2A activator will reduce both α-synuclein and tau pathology in A53T SNCA x MAPT P301S double-transgenic mice, with >40% reduction in each protein vs. monotherapy.

Cross-references: Bridges GBA1/lysosomal hypotheses in PD and h-var-cf5d8c96cb (TFEB Activation in AD).